Lung cancer kills more people in Europe than any other type of cancer, yet efforts to monitor and improve standards of treatment and care have lagged behind those of less fatal cancers, such as breast [more]
Hopes of greatly speeding up the evaluation of new therapies by using tumour response to a short course of neoadjuvant treatment as a surrogate for clinical benefit have proved false and the sooner we recognise [more]
The patient rejects the standard of care. The oncologist cannot answer his question How long do I have? Is the treatment course they agree on second best, or best? This article was first published online [more]